20-Year Steady Increase in Survival of Adult Patients with Relapsed Philadelphia-Positive Acute Lymphoblastic Leukemia Post Allogeneic Hematopoietic Cell Transplantation.
Ali BazarbachiMyriam LabopinMahmoud AljurfRiitta NiittyvuopioMarie BalsatDidier BlaiseIbrahim Yakoub-AghaAnna GrassiHans Christian ReinhardtStig LenhoffPavel JindraJakob PasswegIman Abou DalleMichael StadlerBruno LiourePatrice CeballosEolia BrissotSebastian GiebelArnon NaglerChristoph SchmidMohamad MohtyPublished in: Clinical cancer research : an official journal of the American Association for Cancer Research (2022)
We observed a major progressive improvement in OS from posttransplant relapse for patients with Ph+ ALL over the years, likely multifactorial including transplant-related factors, posttransplant salvage, and improvement in supportive care. These large-scale real-world data can serve as a benchmark for future studies in this setting. See related commentary by Gale, p. 813.
Keyphrases
- acute lymphoblastic leukemia
- allogeneic hematopoietic stem cell transplantation
- free survival
- stem cell transplantation
- healthcare
- multiple sclerosis
- palliative care
- bone marrow
- electronic health record
- current status
- quality improvement
- big data
- case control
- affordable care act
- machine learning
- low dose
- health insurance
- data analysis
- deep learning
- drug induced